What is the Share Price of Solara Active Pharma Sciences Ltd?
- Answer Field
-
The share price of Solara Active Pharma Sciences Ltd for NSE is ₹ 505.15 and for BSE is ₹ 506.40.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, Solara Active Pharma Sciences share price is currently at ₹ 505.15, which is down by ₹ -3.80 from its previous closing. Today, the stock has fluctuated between ₹ 496.05 and ₹ 512.00. Over the past year, Solara Active Pharma Sciences has achieved a return of 15.17 %. In the last month alone, the return has been -8.17 %. Read More...
Particulars | MAR 2025 (Values in Cr) |
---|---|
Revenue | 273.01 |
Operating Expense | 283.84 |
Net Profit | -4.88 |
Net Profit Margin (%) | -1.78 |
Earnings Per Share (EPS) | -1.65 |
EBITDA | 48.54 |
Effective Tax Rate (%) | 0.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 27.76 | 1.99 | 278.64 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 149.35 | 18.67 | 1.49 | 1573.70 | 101.00 / 184.95 |
CIPLA LTD | 1505.40 | 23.06 | 3.89 | 121589.70 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 338.10 | 12.94 | 2.74 | 995.06 | 163.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 36.36 | 5.74 | 278.64 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 697.60 | 39.68 | 6.17 | 2016.81 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 10524.65 | 150.31 | 34.15 | 26311.63 | 6160.25 / 10653.05 |
BLISS GVS PHARMA LTD | 149.35 | 22.80 | 1.48 | 1573.70 | 101.00 / 184.95 |
Key Metric | Value |
Solara Share Price | ₹757.75 |
Revenue (Qtr Sep 2024) | ₹346.95 Cr |
Net Profit (Qtr Sep 2024) | ₹8.02 Cr |
Net Profit Margin | 2.31% |
Earnings Per Share (EPS) | ₹2.11 |
EBITDA | ₹61.64 Cr |
Operating Expense | ₹339.25 Cr |
Key Highlights:
Solara share price increased to ₹757.75, gaining ₹16.20 (2.18%) in the latest trading session.
The company posted revenue of ₹346.95 Cr for the quarter ending September 2024.
Net profit reached ₹8.02 Cr, with a net profit margin of 2.31%.
Earnings Per Share (EPS) stood at ₹2.11, indicating solid financial performance.
The company’s EBITDA was ₹61.64 Cr, reflecting strong operational profitability.
Report Date | Details |
Most Recent Report | September 2024 |
Revenue for the Year | ₹1,350 Cr (Estimated) |
Net Profit for the Year | ₹30.00 Cr (Estimated) |
EPS (Year) | ₹8.50 |
ROE | 0.00% |
Key Highlights:
Solara’s annual report for 2024 estimates revenue of ₹1,350 Cr and net profit of ₹30.00 Cr.
The EPS for the year is estimated at ₹8.50, reflecting good profitability.
Despite the positive figures, the ROE stands at 0.00%, indicating room for improvement in generating returns for shareholders.
Year | Dividend |
Latest Dividend (2021) | ₹3 per share (Final) |
Previous Dividend (2020) | ₹4 per share (Interim) |
Key Highlights:
The Solara share price has seen dividend payouts, with the most recent dividend being ₹3 per share in August 2021.
In November 2020, the company declared a dividend of ₹4 per share as an interim distribution.
Dividend yield for the company stands at 0.00% in the most recent period, reflecting the absence of dividends in recent years.
Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru.
The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this, the Solara Active has two research and development units - in Bengaluru and Chennai - equipped with state-of-the-art facilities and a pipeline of 25+ products, at different stages of development. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.
The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish, World Health Organization (WHO) - Geneva; Medicines and Healthcare products Regulatory Agency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA) - Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan.
The Company acquired 100% of the equity shares of Strides Chemicals Private Limited and made it the wholly owned subsidiary of the Company effective from September 1, 2018. During the year 2018-19, the Company's wholly owned subsidiary Strides Chemicals Private Limited amalgamated with the Company on December 20, 2019 and the merger was given effect in February, 2020.
The Company's new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A-1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam - 531011, Andhra Pradesh, commenced commercial production in 2021.
The Company acquired 487000 additional stake in Sequent Penems Private Limited, subsidiary company and subsequently Sequent Pharma became the wholly owned subsidiary of Company effective from April 27, 2021. In 2024, the Company sold its entire shareholding in Sequent Penems Private Limited to Symbio Generrics India Private Limited and Sequent Penems Private Limited ceased to be a
subsidiary of the Company with effect from April 25, 2024.
.
The share price of Solara Active Pharma Sciences Ltd for NSE is ₹ 505.15 and for BSE is ₹ 506.40.
The market cap of Solara Active Pharma Sciences Ltd for NSE is ₹ 1,818.35 Cr. and for BSE is ₹ 1,822.85 Cr. as of now.
The 52 Week High and Low of Solara Active Pharma Sciences Ltd for NSE is ₹ 882.80 and ₹ 417.15 and for BSE is ₹ 885.95 and ₹ 418.05.
You can trade in Solara Active Pharma Sciences Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 15.17%.
Solara Active Pharma Sciences Ltd share price is for NSE ₹ 505.15 & for BSE ₹ 506.40 as on Jun 13 2025 03:30 PM.
The market cap of Solara Active Pharma Sciences Ltd for NSE ₹ 1,818.35 & for BSE ₹ 1,822.85 as on Jun 13 2025 03:30 PM.
As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Solara Active Pharma Sciences Ltd share is -1686.33.
As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Solara Active Pharma Sciences Ltd share is 302.07.
You can trade in Solara Active Pharma Sciences Ltd shares with Bajaj Broking by opening a demat account.
To buy Solara Active Pharma Sciences Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Solara Active Pharma Sciences Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found